Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-03-26
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 22000000 NOK
Award criteria: Lowest price

Technical requirements: Framework agreements for Dexamethasone Dexavit between Vital Pharma Nordic Aps and Helse Nord RHF, Helse Midt-Norge RHF, Helse Vest RHF and Helse Sør Øst RHF [the Northern Norway Regional Health Authority, the Central Norway Regional Health Authority, the Western Norway Regional Health Authority and the South Eastern Norway Regional Health Authority].
Sykehusinnkjøp HF, Medicines Division (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for (the LIS 1901 competition). The competition included the active ingredients that were in accordance with the tender documentation, annex 3 — the Active Ingredients List.
After the implementation of the competition, a tender offer for parenteral Dexamethasone (ATC code H02AB02) have been received, where the supplier has marketing authorisation for Dexavit. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. No other suppliers have marketing authority for parenteral medicines classified in ATC code H02AB02.
On this basis, LIS intends to enter into contracts between the regional health authorities (the contracting authorities) and Vital Pharma Nordic Aps (the Supplier) for Dexavit as an additional contract to LIS 1901, i.e. the scope and duration of the contract must follow the named procurement (including the access to extend and terminate), without a new competition being announced for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has examined the market situation and is of the opinion that it is not possible to hold a new competition, or that a supplier other than Vital Pharma Nordic Aps can deliver the product in this contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds to implement the procurement without a competition. Refer to the Public Procurement Regulations §13-4, letter b, No. 3.
LIS requests that those who have objections to this submit feedback before the expiry of the waiting period, which is 10 days from the day after the announcement is made public. If no objections are received, a contract will be signed after the waiting period has expired.
Sykehusinnkjøp HF, Medicines Division (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for (the LIS 1901 competition). The competition included the active ingredients that were in accordance with the tender documentation, annex 3 — the Active Ingredients List.
After the implementation of the competition, a tender offer for parenteral Dexamethasone (ATC code H02AB02) have been received, where the supplier has marketing authorisation for Dexavit. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. No other suppliers have marketing authority for parenteral medicines classified in ATC code H02AB02.
On this basis, LIS intends to enter into contracts between the regional health authorities (the contracting authorities) and Vital Pharma Nordic Aps (the Supplier) for Dexavit as an additional contract to LIS 1901, i.e. the scope and duration of the contract must follow the named procurement (including the access to extend and terminate), without a new competition being announced for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has examined the market situation and is of the opinion that it is not possible to hold a new competition, or that a supplier other than Vital Pharma Nordic Aps can deliver the product in this contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds to implement the procurement without a competition. Refer to the Public Procurement Regulations §13-4, letter b, No. 3.
LIS requests that those who have objections to this submit feedback before the expiry of the waiting period, which is 10 days from the day after the announcement is made public. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Vital Pharma Nordic Aps
Award value: 22000000